Patents by Inventor Thomas Hogberg
Thomas Hogberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170217910Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: April 14, 2017Publication date: August 3, 2017Applicant: LEO LABORATORIES LIMITEDInventors: Gunnar GRUE-SØRENSEN, Xifu LIANG, Thomas HÖGBERG, Kristoffer MÅNSSON, Per VEDSØ, Thomas VIFIAN
-
Patent number: 9708286Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: June 24, 2015Date of Patent: July 18, 2017Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø, Thomas Vifian
-
Patent number: 9676698Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: GrantFiled: June 9, 2016Date of Patent: June 13, 2017Assignee: LEO Laboratories LimitedInventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Patent number: 9656945Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: December 22, 2011Date of Patent: May 23, 2017Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø
-
Publication number: 20160280627Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: ApplicationFiled: June 9, 2016Publication date: September 29, 2016Inventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Patent number: 9422309Abstract: The present invention relates to a compound according to formula (I) wherein R1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: June 21, 2013Date of Patent: August 23, 2016Assignee: LEO LABORATORIES LIMITEDInventors: Xifu Liang, Thomas Högberg, Bjarne Nørremark, Kristoffer Månsson, Carsten Ryttersgaard, Gunnar Grue-Sørensen
-
Patent number: 9416084Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: GrantFiled: December 1, 2014Date of Patent: August 16, 2016Assignee: LEO Laboratories LimitedInventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Patent number: 9404131Abstract: The invention relates to methods for preparing ingenol-3-angelate from ingenol or ingenol derivatives.Type: GrantFiled: July 25, 2014Date of Patent: August 2, 2016Assignee: LEO Laboratories LimitedInventors: Xifu Liang, Thomas Hogberg, Gunnar Grue-Sorensen, Thomas S. Moody, Andrew S. Rowan
-
Patent number: 9388124Abstract: The invention relates to compounds of general formula (I) wherein R is (C1-C7)alkyl, (C2-C7)alkenyl or (C2-C7)alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: December 22, 2011Date of Patent: July 12, 2016Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg
-
Patent number: 9303027Abstract: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (?) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.Type: GrantFiled: July 19, 2011Date of Patent: April 5, 2016Assignees: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Pradip Kumar Sasmal, Vamsee Krishna Chintakunta, Vijay Potluri, Ish Kumar Khanna, Ashok Tehim, Mahaboobi Jaleel, Thomas Hogberg, Oystein Rist, Lisbeth Elster, Thomas Michael Frimurer, Lars-Ole Gerlach
-
Publication number: 20150315118Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: ApplicationFiled: December 1, 2014Publication date: November 5, 2015Inventors: Thomas Hogberg, Gunnar Grue-Sorensen, Xifu Liang, Anne Marie Homeman, Anders Klarskov Petersen
-
Publication number: 20150291551Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: June 24, 2015Publication date: October 15, 2015Applicant: LEO Laboratories LimitedInventors: Gunnar GRUE-SØRENSEN, Xifu LIANG, Thomas HÖGBERG, Kristoffer MÅNSSON, Per VEDSØ, Thomas VIFIAN
-
Patent number: 9102687Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: GrantFiled: December 22, 2011Date of Patent: August 11, 2015Assignee: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø, Thomas Vifian
-
Publication number: 20150175622Abstract: The present invention relates to a compound according to formula (I) wherein R1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: ApplicationFiled: June 21, 2013Publication date: June 25, 2015Applicant: LEO LABORATORIES LIMITEDInventors: Xifu Liang, Thomas Högberg, Bjarne Nørremark, Kristoffer Månsson, Carsten Ryttersgaard, Gunnar Grue-Sørensen
-
Publication number: 20150024443Abstract: The invention relates to methods for preparing ingenol-3-angelate from ingenol or ingenol derivatives.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Inventors: Xifu Liang, Thomas Hogberg, Gunnar Grue-Sorensen, Thomas S. Moody, Andrew S. Rowan
-
Patent number: 8901356Abstract: The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.Type: GrantFiled: July 8, 2011Date of Patent: December 2, 2014Assignee: Leo Laboratories LimitedInventors: Thomas Högberg, Gunnar Grue-Sørensen, Xifu Liang, Anne Marie Horneman, Anders Klarskov Petersen
-
Publication number: 20140303150Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: December 22, 2011Publication date: October 9, 2014Applicant: LEO Laboratories LimitedInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø, Thomas Vifian
-
Publication number: 20130331446Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: December 22, 2011Publication date: December 12, 2013Applicant: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø
-
Publication number: 20130324600Abstract: The invention relates to compounds of general formula (I) wherein R is (C1-C7)alkyl, (C2-C7)alkenyl or (C2-C7)alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.Type: ApplicationFiled: December 22, 2011Publication date: December 5, 2013Applicant: LEO LABORATORIES LIMITEDInventors: Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg
-
Publication number: 20130303525Abstract: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (?) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.Type: ApplicationFiled: July 19, 2011Publication date: November 14, 2013Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY;S LABORATORIES LTD.Inventors: Pradip Kumar Sasmal, Vamsee Krishna Chintakunta, Vijay Potluri, Ish Kumar Khanna, Ashok Tehim, Mahaboobi Jaleel, Thomas Hogberg, Oystein Rist, Lisbeth Elster, Thomas Michael Frimurer, Lars-Ole Gerlach